Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
07 February 2019Website:
http://www.alector.comNext earnings report:
07 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 25 Oct 2024 20:42:02 GMTDividend
Analysts recommendations
Institutional Ownership
ALEC Latest News
OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach.
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:
Alector, Inc. (NASDAQ:ALEC ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Katie Hogan – Senior Director-Corporate Communications and Investor Relations Arnon Rosenthal – Co-Founder and Chief Executive Officer Sara Kenkare-Mitra – President and Head-Research and Development Gary Romano – Chief Medical Officer Marc Grasso – Chief Financial Officer Conference Call Participants Michael Reid – Morgan Stanley Carter Gould – Barclays Tom Shrader – BTIG Sarah Schram – William Blair & Company Ananda Ghosh – H.C. Wainwright & Company Graig Suvannavejh – Mizuho Securities Corinne Jenkins – Goldman Sachs Operator Good afternoon, ladies and gentlemen, and welcome to the Alector Second Quarter and Midyear 2024 Earnings Conference Call.
Alector (ALEC) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to earnings of $0.02 per share a year ago.
Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT
--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer's disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative study population that enables testing of the effects of a novel TREM2 agonist in early AD--
Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation
Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript
Alector (ALEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Alector (ALEC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What type of business is Alector?
Alector, Inc. is a clinical-stage biopharmaceutical company that is developing ways to treat neurodegenerative diseases using expertise in neurology, immunology, and human genetics. Founded in 2013 with headquarters in South San Francisco. The company calls itself a pioneer in immuno-neurology - a new therapeutic approach to treating neurodegeneration that considers immune dysfunction as the root cause of many pathologies that drive degenerative brain diseases. The company is developing treatments that simultaneously counteract these pathologies and restore the brain's immune system. Alector has developed its own Discovery platform, which uses large sets of human genetic data, advanced tools in bioinformatics and visualization, and developments in neurodegeneration and immunology.
What sector is Alector in?
Alector is in the Healthcare sector
What industry is Alector in?
Alector is in the Biotechnology industry
What country is Alector from?
Alector is headquartered in United States
When did Alector go public?
Alector initial public offering (IPO) was on 07 February 2019
What is Alector website?
https://www.alector.com
Is Alector in the S&P 500?
No, Alector is not included in the S&P 500 index
Is Alector in the NASDAQ 100?
No, Alector is not included in the NASDAQ 100 index
Is Alector in the Dow Jones?
No, Alector is not included in the Dow Jones index
When was Alector the previous earnings report?
No data
When does Alector earnings report?
The next expected earnings date for Alector is 07 November 2024